Sepracor's 'boxing bed' ad hit with DDMAC untitled letter

Share this article:
Regulators rapped Sepracor’s “boxing bed” ad for making misleading claims about efficacy and MOA
Regulators rapped Sepracor’s “boxing bed” ad for making misleading claims about efficacy and MOA
A 60-second TV ad for insomnia drug Lunesta, which portrayed a woman fighting for sleep in a bed-turned-boxing ring, drew an untitled letter from regulators.

The Division of Drug Marketing, Advertising, and Communications (DDMAC) said the ad made misleading claims, suggesting that Lunesta is clinically superior to other medications in second-line use and that its mechanism of action (MOA) is more precise than the package insert suggests. It was one of three marketing pieces cited by the division last week; a DTC patient brochure for Auxilium's Xiaflex and a sales aid for Cumberland's Acetadote also elicited letters.

The Lunesta ad opened with the clanging of a boxing bell and panned back to reveal a woman sitting in bed in the middle of the night, her bed bounded by the ropes of a boxing ring. “If you've taken your sleep aid, and you're still fighting to sleep in the middle of the night,” states the voiceover, “…ask your doctor about switching to Lunesta and discover a restful Lunesta night.”

Promotional materials cannot suggest that a drug is safer or more effective than another, when this has not been shown clinically, DDMAC's regulatory review officer noted.

The ad's characterization of Lunesta's MOA—“It  keys into receptors that support sleep, setting your sleep process in motion”—also  raised eyebrows at DDMAC, which said this claim implies that Lunesta's MOA is specific for and only affects the sleep-cycle. “This is not the case,” wrote DDMAC. “Lunesta also carries many potential risks for serious adverse effects, including the potential for abuse or dependence.

Near the end of the commercial, the voiceover mentions several side effects, including abnormal behavior, worsening of depression and allergic reactions. Viewers are directed to a print ad in US News & World Report. DDMAC demanded stoppage of the ad by Sepracor, which markets Lunesta, and a written response from the company.

The Lunesta DTC account is handled by Interpublic Group's Lowe. Sepracor moved the business to Lowe last September, after stopovers at Publicis' Kaplan Thaler Group and IPG's McCann HumanCare.

Lunesta posted 2009 US sales of $813 million, according to SDI.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...